Novo Nordisk A/S (NYSE:NVO)
| 72.15 Delayed Data As of Apr 16 |  +0.64 / +0.89%Today’s Change | 60.92 Today|||52-Week Range 75.86 | +3.29% Year-to-Date |
Latest NVO News | Press Releases
| AstraZeneca (AZN) Farxiga COVID-19 Study Fails to Meet Goal Apr 13 / Zacks.com - Paid Partner Content | With a New Diabetes Product Coming to Market, What Lies Ahead for Zealand Pharma Investors? Apr 12 / MotleyFool.com - Paid Partner Content |
Today’s Trading
| Previous close | 71.51 |
| Today’s open | 72.19 |
| Day’s range | 71.94 - 72.40 |
| Volume | 1,320,611 |
| Average volume (3 months) | 1,007,502 |
| Market cap | $124.5B |
Data as of 3:59pm ET, 04/16/2021
Growth & Valuation
| Earnings growth (last year) | +12.27% |
| Earnings growth (this year) | +6.28% |
| Earnings growth (next 5 years) | +10.00% |
| Revenue growth (last year) | +6.13% |
| P/E ratio | 24.9 |
| Price/Sales | 8.42 |
| Price/Book | 15.58 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| SNYSanofi | +0.60 | +1.18% |
| AZNAstraZeneca | -0.10 | -0.20% |
| BMYBristol-Myers Squibb | +1.02 | +1.58% |
| GSKGlaxoSmithKline | +0.08 | +0.21% |
Data as of 4:00pm ET, 04/16/2021
Financials
| Next reporting date | May 5, 2021 |
| EPS forecast (this quarter) | $0.81 |
| Annual revenue (last year) | $19.4B |
| Annual profit (last year) | $6.4B |
| Net profit margin | 33.19% |
Profile
Sector Health Technology |
Industry Pharmaceuticals: Major |
No executives to display |
Corporate headquarters Bagsværd, Capital Region |
Forecasts
